KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) EBITDA: 2009-2025

Historic EBITDA for Exact Sciences (EXAS) over the last 17 years, with Sep 2025 value amounting to -$25.5 million.

  • Exact Sciences' EBITDA rose 35.17% to -$25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 316.35%. This contributed to the annual value of -$1.0 billion for FY2024, which is 387.74% down from last year.
  • As of Q3 2025, Exact Sciences' EBITDA stood at -$25.5 million, which was down 1,089.25% from -$2.1 million recorded in Q2 2025.
  • Over the past 5 years, Exact Sciences' EBITDA peaked at $6.8 million during Q3 2023, and registered a low of -$876.4 million during Q4 2024.
  • Moreover, its 3-year median value for EBITDA was -$67.8 million (2023), whereas its average is -$126.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 104.96% in 2023, then plummeted by 1,191.77% in 2024.
  • Quarterly analysis of 5 years shows Exact Sciences' EBITDA stood at -$221.4 million in 2021, then skyrocketed by 46.32% to -$118.9 million in 2022, then surged by 42.93% to -$67.8 million in 2023, then crashed by 1,191.77% to -$876.4 million in 2024, then skyrocketed by 35.17% to -$25.5 million in 2025.
  • Its EBITDA stands at -$25.5 million for Q3 2025, versus -$2.1 million for Q2 2025 and -$96.0 million for Q1 2025.